Skip Navigation
Explore our COVID-19 Resources and Updates
CHS blue logo square
 
 
Home > Our Work > All Publications > 2013

Publications

Our publications keep professionals working across the public, private, and academic sectors informed on the most important developments and issues in health security and biosecurity.

Find an article or report by keywords:

 
 
Find an article or report or see all by area, author, or year:

Title:

Next-Generation Monoclonal Antibodies: Challenges and Opportunities

Image of Report Cover: Next Generation Monoclonal Antibodies
Authors:
Gigi Kwik Gronvall, Kunal J. Rambhia, Amesh Adalja, Anita Cicero, Tom Inglesby, Robert Kadlec
Date posted:
February 15, 2013
Publication type:
Report
Publication:

Center for Biosecurity of UPMC, February 15, 2013

Publisher:
This project was supported by DTRA Chem Bio Directorate, and in collaboration with TASC, Inc, under contract #HDTRA1-11-D-0004.
Introduction:

The Center for Biosecurity of UPMC conducted this study to provide leaders in the US Department of Defense (DOD) with an expert assessment of the technical feasibility and strategic implications of next-generation monoclonal antibodies (mAbs) as medical countermeasures (MCMs) for DOD personnel. Our assessment includes identification of potentially appropriate DOD investments in mAb technologies.


Summary of Findings

As a technology platform, monoclonal antibodies have value for DOD as a defense against bioweapons and emerging infectious diseases.

Monoclonal antibodies have great potential usefulness to counter biological warfare agents and naturally occurring infectious disease threats that are not addressed by currently available countermeasures. Monoclonals display exquisite specificity, are able to recruit additional host immune components to fight infection, confer near-immediate immunity once administered, can be successfully administered to all populations regardless of current immune status, and have a generally low rate of adverse reactions. Further, mAbs may offer pre- and postexposure protection in addition to potential therapeutic benefits, even in the case of antibiotic resistance. There is also a body of scientific evidence that mAbs may be effective in treating disease caused by biological warfare and natural pathogens of concern to DOD.

Although commercial development of mAb technologies is mature, mAbs are not commonly used to prevent or treat infectious diseases.

Monoclonal antibodies have become a commercial blockbuster drug platform, with the biggest portion of sales growth in the pharmaceutical industry. However, the concentrated effort in monoclonal antibody development has focused on oncological indications and immunological diseases, such as rheumatoid arthritis (RA). There is one commonly used licensed product for prevention of respiratory syncytial virus (RSV) in premature babies, another recently FDA approved for inhalational anthrax disease, and a handful of mAb products undergoing clinical evaluation for infectious disease indications, including methicillin-resistant Staphylococcus aureus and Clostridium difficile.

mAbs are poised to play a critical role in infectious disease management.

In spite of the lack of commercial attention to infectious disease mAbs, there are a number of reasons to believe they may be more desirable in the future, because of the declining clinical effectiveness of antibiotics; the large number of immunocompromised people who could benefit from mAbs; the growing recognition of the microbiome, which is disrupted by antibiotics; and the increased availability of diagnostic tests that may make mAbs more feasible to administer. In addition, because many infectious disease indications may require administration of a cocktail of mAbs, it is encouraging that the FDA has allowed cocktails of mAbs to be clinically tested as one product.

High cost per dose is a hallmark of mAbs, but costs are dropping.

Monoclonal antibodies are expensive. As a biologic class of drugs, they cost more to manufacture than small-molecule drugs, and FDA-licensed mAbs are currently among the most expensive drugs for patients and insurance companies. Many factors contribute to the cost of a particular mAb, but the most important factor influencing their price appears to be the market—the market will bear a high cost for mAbs, so they carry a big price tag. Some indicators suggest the cost of mAbs is dropping; this has been attributed to insurance company actions and greater mAb manufacturing standardization.

Monoclonal antibody products have greater regulatory success than other drug classes, but all biodefense products share common regulatory risks.

Monoclonal antibodies, in general, do not carry as much regulatory risk as other medical countermeasures, and the FDA has recent and historical experience with evaluating mAb products. This makes mAbs especially attractive for DOD, which is required to use only FDA-approved MCMs for prevention and treatment. However, biodefense products in general are riskier than other MCMs because they often require application of the FDA Animal Efficacy Rule, which allows for FDA approval based on animal model efficacy data and human safety data.

Areas for Action by DOD

As a class, mAbs will not replace vaccines or drugs in a complex MCM strategy, but they can be an important adjunct of a comprehensive approach that may be well-suited for specific DOD populations and for specific pathogens. Therefore, the question confronting DOD is not whether mAbs should be employed, but how to use mAbs technologies effectively. This report recommends that DOD take the following actions to take advantage of mAb technologies:

  • Include mAbs as part of the DOD medical countermeasure strategy.
  • Develop a library of mAbs that are IND-ready (ie, have attained investigational new drug status) and can be used as prophylaxis or treatment against a range of pathogens.
  • Consider fast-tracking 3 mAbs for development as a proof of concept: one for treatment of a high-risk bacterial pathogen, one for prophylaxis against a fast-moving virus, and one for prophylaxis against a toxin.
  • Establish partnerships with mAb developers by describing clear, specific requirements for mAbs that will be needed and pursued.
  • Engage private industry and academia in mAb research and development (R&D) through clearly defined research partnerships, such as precompetitive consortia to develop new mAb technologies, which may also accelerate the lowering of production costs.
  • Invest in R&D for improved means of mAb administration that meet DOD operational requirements.
  • Leverage R&D of mAbs to enhance ongoing efforts to develop rapid point-of-care diagnostics.

 

 

Our Mission

To protect people’s health from epidemics and disasters and ensure that communities are resilient to major challenges.